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Abstract 
The bioanalytical method validation of fenofibrate was performed with all the basic parameter by HPLC using 
human plasma. This research paper describes a specific procedure for validation of Fenofibrate in human plasma [1-2]. The 
mobile phase used was simple and column friendly and was sufficiently sensitive to quantify fenofibrate in amounts as low 
as 0.095µg/ml. This limit of quantitation (LOQ) was determined as the lowest concentration with a coefficient of variation 
lower than 20% and the total accuracy of the method ranged from 101.99 to 107.41%. The LOQ of this method is better 
than those of other reported methods. The calibration curve plotted concentration versus area and was linear from 0.095 
µg/ml to 19.924 µg/ml, having r
2
 greater than 0.98 during the course of validation. The above method is valid for the 
analysis of drug in human plasma. The method with slight modification could be used for the drug analysis in various 
dosage forms [2-4]. 
Keywords: Fenofibrate, LOQ, Bioanalytical method validation 
 
1. Introduction 
After developed an analytical methods or bio-
analytical method for the quantitative determination of 
drugs and their metabolites in biological samples play a 
important role for the study and interpretation of 
bioavailability, bioequivalence and pharmacokinetic data. 
Chromatographic analytical methods are commonly used in 
regulatory laboratories for the qualitative and quantitative 
analysis of drug substances, drug products, raw materials 
and biological samples through all phases of drug 
development and from research to quality control. 
Throughout the drug development process, method 
validation is carried out to ensure that an analytical method 
is accurate, specific, reproducible and rugged over the 
specific range in which the analyte will be analysed. All the 
stability of a drug in a biological matrix is also important 
such as bench top stability, freeze-thaw stability, stability 
in the auto sampler and long term stability [3-4].  
 
2. Experimental 
2.1 Sample Preparation  
Samples of 700 µl of plasma were taken. To this 
50 µl (75 µg/ml) of Diazepam as internal standard (IS) was 
added. The samples were vortex mixed for about 2 min and 
100 µl of 0.1 N hydrochloric acid and 5.0 ml ethyl acetate 
were also added. The contents were transferred to a shaker 
for 15 min at 100 rpm and centrifuged for 3 min at 5°C. 
Then 5.0 ml of the upper organic layer were transferred and 
evaporated under N2 gas at100psi and 50° C. The sample 
was finally reconstituted with 400 µl of mobile phase, 
transferred into the chromatography vials and 100 µl 
injected [5-7].  
2.2 Chromatographic Conditions  
The following parameters were used for the 
developed method and chromatograms were obtained for 
the drug and IS aqueous mixtures, extracted blank plasma 
sample, extracted blank plasma with IS sample and 
extracted blank plasma with drug.(Table-I) 
2.2 Validation 
2.2.1 System Suitability  
This parameter was performed by running six 
injections of drug dilution. Coefficient of variation in 
percentage (%CV) of areas and retention times were 
calculated. %CV of area was less than 2% and that of the 
retention times was less than 5%, which is within the 
acceptable range.   
2.2.2 Precision:  
The precision of the developed method based on 
within-day repeatability was determined by replicate 
analysis of six sets each of high, middle and low quality 
control samples. The reproducibility (day-to-day variation) 
of the method was validated using similar six sets of high, 
middle and low quality control samples on different days.  
2.2.3 Accuracy:  
Accuracy of the developed method was 
determined by replicate analysis of six sets of sample at 
high, middle and low quality control concentrations and 
comparing the difference between the spiked value 
(nominal) and that actually found. Accuracy was expressed 
as percentage of the nominal concentration.  
2.2.4 Recovery:  
In Bio-analytical method development the 
analytical recovery of sample preparation procedure of 
Fenofibrate and the internal standard (Diazepam) was 
estimated by comparing the peak areas obtained from 
plasma samples (extracted) at three concentration levels 
(LQC, MQC, HQS), with equivalent amounts of and IS 
Diazepam in aqueous solution.  
2.2.5 Selectivity:  
In Bio-analytical method development the 
selectivity of the method was verified by checking the 
interference of endogenous compounds in human plasma at 
the retention time of the drug and IS by evaluating six lots 
of plasma [9-12].  
 
2.2.6 Stability  
Stability parameter was evaluated by determining 
the following five parameters:  
A. Stock solutions stability-  
 The drug stock solution was evaluated by injecting 
six replicate samples of old stock solutions and comparing 
the response with freshly prepared stock solution. The 
stock solution stability of the internal standard stock was 
evaluated by the same process.  
B. Bench top stability-  
The bench top was stability was determined at 
lower and higher quality control samples by evaluating 6 
replicate samples at each level. The samples were 
processed after keeping them at bench top (room 
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temperature) for about 2 hours and then analyzed against 
freshly spiked calibration curve standards.  
C. Freeze-thaw stability-  
The freeze-thaw stability in matrix was studied by 
assaying six replicates of QC samples at low and high 
concentrations previously frozen and thawed over three 
cycles against freshly spiked calibration standards. The 
samples were first frozen at -27
0
C for at least 40 hours 
followed by unassisted thawing at room temperature. The 
samples were again frozen for at least 12 hours under the 
same conditions. This freeze-thaw cycle was repeated two 
more times and the samples were then processed after the 
third cycle and analyzed.  
D. Auto sampler stability- Stability in the auto sampler 
was assessed by extracting six   replicates of QC samples at 
low and high concentration and putting the processed 
samples in the atmosphere. The samples were injected after 
120 hours along with freshly spiked calibration standards.  
E. Long-term stability- The long-term evaluation was 
performed following a storage   period of about 60 days. 
Six replicates of the stored low and high concentration QC 
samples were removed from the freezer/cold room and 
allowed to thaw. The samples were processed and analyzed 
against freshly spiked calibration standards [10-12].  
2.3 Validation Study  
After optimization of the analytical conditions, the 
evaluation of parameters such as selectivity, accuracy, 
precision, linearity, recovery (drug and internal standard), 
stability (freeze-thaw, bench top, auto sampler, long term, 
stock solution stability), ruggedness and dilution integrity 
were performed for the validation of the method. 
2.4 Selectivity  
Six lots of blank plasma were evaluated and an 
interfering peak was observed at the retention time of the 
drug, but the area of the interfering peak was small and 
insignificant. There were no interfering peaks at the 
retention time of the internal standard (Table II).  
2.5 Precision and Accuracy  
Precision and accuracy of the method was 
characterized by running five analytical batches; each batch 
contained the following samples:  
(a) A reference standard solution (one sample, mixture with 
internal standard) 
(b) Blank matrix (in duplicate)  
(c) Blank matrix with internal standard (in duplicate)  
(d) Spiked calibration standards (1set of 8 non-zero 
concentrations)  
(e) Limit of quantitative quality control (LOQQC) (6 
samples)  
(f) Lower quality control (LOQ) (6 samples)  
(g) Middle quality control (MQC) (6 samples)  
(h) Higher quality control (HQC) (6 samples)  
2.5.1 Precision: The precision of the method was measured 
by the present coefficient of   variation (%CV) over the 
concentration range of high, middle and low quality control 
samples, respectively, of the drug during the course of 
validation. Within batch/interbatch precision of the method 
ranged from 1.14 to 6.90%.  
2.5.2 Accuracy:  
The accuracy of the assay is defined as the peak 
area ratio response of the drug   and internal standard 
versus concentration of the quality control sample to their 
respective nominal values, expressed as percentage. Within 
batch accuracy: Within batch accuracy of the method for 
the drug was found in the range of 90.30 to 110.60%. 
Between batch/inter batch or total accuracy: The total 
accuracy of the method ranged from 101.99 to 107.41%.  
2.6 Linearity:   
  The linearity of the method was determined by a 
weighted least square regression analysis of standard plot 
associated with an eight point standard curve. The 
calibration curve plotted concentration versus area (Table 
III) and was shown to be linear from 0.095µg/ml to 19.924 
µg/ml as shown in fit calibration lines of peak are response 
of drug and internal standard versus concentration of 
calibration standards were determined by weighted least 
square regression analysis with a weighting factor 1/X
2
. 
The regression coefficient (r
2
) were consistently greater 
than 0.98 during the course of validation [12-14].                                       
Statistical parameters for the calibration curve  
 Y = 0.4734 X  
 r2 = 0.9927  
 r = 0.9885  
     2.7 Recovery  
The percentage recoveries for the drug and the 
internal standard were determined by comparing the peak 
areas of the response of drug extracted from plasma quality 
control samples with that of the peak areas of un extracted 
aqueous standard samples containing the same 
concentration of the drug and the internal standard. The 
present recoveries were calculated at each QC 
concentration by the following equation. 
 
% Recovery = Mean peak response of extracted 
samples/Mean peak response of non-extracted samples  
 
The total recovery of the drug was 58.21 to 
64.20% (mean recovery=60.86%) and that of the internal 
standard was 79.05%. (Tables IV)  
2.8 Stability  
Stock solution stability: The stability of drug stock 
solution was evaluated by injecting a dilution of 3.808 
mg/ml solution of the stock. The results indicate the 
stability of the stock solution over a minimum of 15 days 
period when stored at or below 100 °C [12-14]. (Table V)  
 
3. Results 
Table I: Chromatographic Condition 
1 Column Lithosphere 60 RP-Select B 250x4mm ; 5 µm 
2 Column Temp 35°C 
3 Flow Rate 0.5 to 1.5 ml/min 
4 Detector UV at 287 nm 
5 Mobile phase Phosphate buffer (pH 6.5) and Acetonitrile (75:25) 
6 Injection volume: 100 µl 
7 Retention Time 
       Fenofibrate   
       Diazepam  
 
6.5. to 7.5 min 
5.5 to 6.5 min 
 
Research Article                                                                                Mohamad Taleuzzaman et al/2015
 
 
                                                            78 
 
Table II: Blank Plasma screening (Selectivity) 
S. 
No. 
Blanks 
Interference at analyte 
RT (Area) 
LOQ Area 
% 
LOQ 
Interference at 
analyte IS (Area) 
IS Area 
% 
IS 
1 BLK-01 0 13138 0.0 0 354711 0.0 
2 BLK-02 0 13670 0. 0 372688 0.0 
3 BLK-03 56 13878 0.48 0 365678 0.0 
4 BLK-04 475 14235 5.01 0 370354 0.0 
5 BLK-05 0 14790 0.0 0 393184 0.0 
6 BLK-06 325 14123 2.67 0 389432 0.0 
 Mean  13972.33   374341.2  
 SD  509.36   13302.94  
 
Table III: Linearity 
Concentration ratio 
(Drug: IS) 
Area Ratio 
(Drug :IS) 
0.095 0.0 
0.190 0.1 
0.381 0.2 
1.088 0.5 
3.108 1.6 
10.361 4.4 
15.940 7.6 
19.924 8.4 
 
 
Table-IV (Recovery) 
% Recovery 
QC LQC MQC HQC 
1 67.67 60.92 58.84 
2 64.67 63.34 57..55 
3 61.92 64.90 60.60 
4 69.60 58.92 53.98 
5 62.70 54.62 57.98 
6 65.50 60.93 60.70 
Mean 64.30 60.05 58.21 
S.D.(+/-) 2.7 3.34 2.26 
C.V.(%) 4.2 5.5 3.8 
N 6 6 6 
Table-V (Stability) 
Stock solution stability of Fenofibrate stored at refrigerated temperature between 1-10 °C 
Stability stock Comparison Stock 
Old Response New Response 
1 38680 1 38740 
2 38195 2 38385 
3 37985 3 38485 
4 38540 4 37700 
5 38720 5 38500 
6 38450 6 38400 
Mean 38428.5  38368.5 
S.D. 262.14  320.68 
C.V.% 0.6  0.8 
% Stability 99.84  99.84 
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4. Conclusions 
The method was subjected to complete validation 
and all the parameters showed results within the acceptance 
limits. A linear response between the concentration ranges 
of (0.095 µg/ml to 19.924 µg/ml) was obtained. The limit 
of quantitation using 450 µl of plasma was 0.095 µg/ mL. 
The accuracy and precision of the method was evaluated by 
peak area response of the drug and internal standardThe 
total precision (% CV) and accuracy (% normal) for the 
drug ranged from 4.35 to 8.38% and 101.99 to 107.41%, 
respectively. The mean recovery of the drug and IS was 
found to be 62.9 and 78.2% respectively.  
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